#VisualAbstract: Semaglutide improves symptoms in patients with heart failure
1. In this randomized controlled trial, in patients with heart failure with preserved ejection...
Read MoreNov 16, 2023
1. In this randomized controlled trial, in patients with heart failure with preserved ejection...
Read MoreNov 16, 2023
1. Redo-TAVR had low procedural complication rates and was comparable to native-TAVR in terms of...
Read MoreNov 16, 2023
1. In this retrospective population-based study, vaccination against COVID-19 among those over age...
Read MoreNov 15, 2023
Bookmark1. In this meta-analysis, both high-intensity interval training and moderate-intensity...
Read MoreNov 15, 2023
Bookmark1. In this randomized controlled trial, compared to placebo, dexamethasone did not improve...
Read MoreNov 15, 2023
Bookmark1. In this randomized controlled trial, percutaneous coronary intervention (PCI) performed...
Read MoreNov 15, 2023
Bookmark1. Efficacy of spesolimab appeared to be dose-dependent with high-dose spesolimab leading...
Read MoreNov 14, 2023
Bookmark1. A greater percentage of patients who received concurrent stereotactic radiation therapy...
Read MoreNov 14, 2023
Bookmark1. Progression-free survival was 6.3 months for the amivantamab–chemotherapy group, 8.3...
Read MoreNov 14, 2023
Bookmark1. In this randomized controlled trial, in patients with treatment-resistant depression...
Read MoreNov 14, 2023
Bookmark1. In this randomized controlled trial, tight versus liberal blood glucose control...
Read MoreNov 12, 2023
Bookmark1. This randomized clinical trial showed that very low birth weight (VLBW) infants who...
Read MoreNov 11, 2023
Bookmark1. In this systematic review, adolescents (aged 10-19 years) showed clinical improvements...
Read MoreNov 11, 2023
Bookmark Click here to read this study in NEJM. VA design by Bryan Sun. ©2023 2 Minute Medicine,...
Read MoreNov 11, 2023
Bookmark1. In this randomized controlled trial, in patients with heart failure with preserved...
Read MoreNov 11, 2023
Bookmark 1. Median overall survival and progression-free survival were greater in the tebentafusp...
Read MoreNov 11, 2023
Bookmark1. This randomized placebo-controlled clinical trial found that the daily use of...
Read MoreNov 10, 2023
Bookmark Click here to read this study in NEJM. VA design by Bryan Sun. ©2023 2 Minute Medicine,...
Read MoreNov 10, 2023
Bookmark1. In this randomized controlled trial, over a period of 240 weeks, solanezumab did not...
Read MoreNov 10, 2023
Bookmark1. This phase 3 randomised trial demonstrated that compared with placebo in combination...
Read More